Biomarkers for avelumab plus axitinib in advanced kidney cancer

The discovery of a reliable biomarker for how patients with advanced renal cell carcinoma (RCC) will respond to treatment has been very difficult to find. In this study, baseline samples from RCC tumours from patients in the phase III JAVELIN Renal 101 trial were analysed. The study showed that neither the presences of a biomarker […]

read more

ESMO Virtual 2020: Biomarker-guided therapy in metastatic kidney cancer

Yesterday, findings from the phase 2 biomarker trial, BIONIKK, were presented at the European Sociaety of Medical Oncology (ESMO) virtual congress. The study showed clinical evidence that biomarker-guided first-line therapy could be used to enrich responses in patients with metastatic clear cell renal cell carcinoma (RCC). The trial included 154 patients treated with nivolumab or […]

read more

ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer

Non-clear cell renal cell carcinoma (RCC) accounts for about 25% of all RCC diagnoses and usually has worse outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have shown preliminary activity in non-clear cell RCC. Cabozantinib appears to enhance the response to immune checkpoint inhibitors and has shown encouraging results in combination with […]

read more

ESMO Virtual 2020: Nivolumab plus cabozantinib for first-line advanced kidney cancer

At the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Dr Choueiri from Dana Farber Cancer Institute in Boston, USA presented the results of the phase 3 CheckMate-9ER trial evaluating the combination of nivolumab and cabozantinib compared to sunitinib in the first-line treatment of patients with advanced or metastatic renal cell carcinoma (RCC). Each […]

read more

First-line treatment of kidney cancer

These two videos with Dr Eric Jonasch from MD Anderson Cancer Center and Dr Elizabeth Plimack from Fox Chase Cancer Centre, both in the USA, explain how clinicians choose between the first-line treatments that are available for the treatment of renal cell carcinoma (RCC) and the long term control of the disease. Watch the video […]

read more

Advances in systemic treatments for metastatic kidney cancer

In this video interview Professor Jens Bedke from the Department of Urology, Eberhard Karls University Tübingen in Germany discusses the transformation in the first-line treatment of renal cell carcinoma (RCC) from tyrosine kinase inhibitors (TKIs), which was the standard of care, to combination therapies. First-line treatment with a combination of an immune checkpoint inhibitor and […]

read more

Association between TKI-induce high blood pressure and outcomes in patients with kidney cancer

In this retrospective study published in Cancer Reports the association between TKI-induced high blood pressure (hypertension) and treatment outcomes was reported. Fifty-two (52) patients with metastatic renal cell carcinoma (RCC) treated with first-line sunitinib, pazopanib, sorafenib, axitinib, or cabozantinib were examined for any association between TKI-induced hypertension and treatment outcomes. The study found that patients […]

read more

Safety and efficacy of apatinib for metastatic kidney cancer

A recent study coming out of China has identified a new oral tyrosine kinase inhibitor (TKI) with promising safety and efficacy for metastatic renal cell carcinoma (RCC). Anti-angiogenic treatments, such as the TKIs sunitinib, pazopanib and axitinib, play an important role in the treatment of metastatic RCC. A new TKI called apatinib targets the vascular […]

read more

First-line therapy for metastatic kidney cancer: Is two better than one?

An educational symposium was held from 8-10 August as part of the American Society of Clinical Oncology’s (ASCO) Annual Meeting. In his presentation, Dr Primo Lara from UC Davis Comprehensive Cancer Center in California discussed the first-line treatment of metastatic renal cell carcinoma (RCC), specifically whether combination therapy is better than single therapy (monotherapy). Dr […]

read more

The impact of COVID-19 pandemic on treatment for metastatic kidney cancer

A recent online survey involving 41 kidney cancer experts worldwide looked at the changes made to their clinical practice for the treatment of metastatic renal cell carcinoma (RCC) during the COVID-19 pandemic. The majority of the experts prescribed immunotherapy combination treatment for untreated metastatic RCC patients. The survey showed an increase in the use of […]

read more
Showing 1 to 10 of 131 results
  TOP